Description
Retinoic Acid (Highly Pure) Catalog B2010985 (100 mg)
| Catalog | B2010985 |
| Lot | Batch dependent |
| Expiration | Batch dependent |
| Amount | 100 mg |
| Molecular Weight | 300.4 g/mol |
| Supplied As | Powder |
| Applications | Molecular tool for various biochemical studies |
| Storage | 20 C |
| Keywords | Vitamin A Acid, all-trans-Retinoic Acid, Tretinoin, all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid, ATRA |
| Grade | Biotechnology grade; All solutions made with Type I ultrapure water (resistivity>18 Mcm) and filtered through 0.22 m |
Highly pure all-trans-retinoic acid (ATRA), an essential morphogen and transcriptional regulator used for advanced biochemical and developmental studies. Retinoic Acid (Highly Pure) (Catalog B2010985, 100 mg) is a biotechnological-grade, powder-form molecular reagent. As the active form of vitamin A, ATRA serves as a potent signaling molecule that regulates gene expression via nuclear receptors and is pivotal in studies of cell differentiation, embryogenesis, and tissue development.
Designed for maximal stability and experimental fidelity, this formulation supports reproducible results across in vitro and ex vivo models exploring differentiation pathwayssuch as neural or epithelial lineage specificationand in studies of retinoid-mediated metabolism, skin biology, and oncogenesis. Its consistent purity and physicochemical track record make it a staple reagent in stem cell protocols, retinoid pharmacology, and developmental toxicology. Custom-scale quantities are available to support extended research undertakings.
Stored under 20 C conditions and produced following strict biotech-grade protocolsincluding ultrapure water preparation and microfiltrationthis reagent ensures long-term stability and integrity. As with all products in this category, this compound is strictly for Research Use Only (RUO) and is not intended for diagnostic, therapeutic, or human use.
Why researchers choose this product:
- High-purity ATRA for consistent cell differentiation and gene regulation assays
- Reliable formulation minimizes batch variation and ensures reproducibility
- Compact powder format enables precise dosing and extended storage stability
- Fundamental tool in stem cell biology, developmental studies, and retinoid pharmacology
- Scaled quantities available to support long-term or high-throughput research workflows
Indication for Use:
This product is for Research Use Only (RUO). It is not intended for diagnostic, therapeutic, or clinical use.
References:
- 1: Szymaski , Skopek R, Palusiska M, Schenk T, Stengel S, Lewicki S, Kraj L, Kamiski P, Zelent A. Retinoic_Acid and Its Derivatives in Skin Cells. 2020 Dec 11;9(12):2660.
- 2: Ghyselinck NB, Duester G. Retinoic_acid signaling pathways Development. 2019 Jul 4;146(13):dev167502.
- 3: Janesick A, Wu SC, Blumberg B. Retinoic_acid signaling and neuronal differentiation Cell Mol Life Sci. 2015 Apr;72(8):1559-76.
- 4: Siddikuzzaman, Guruvayoorappan C, Berlin Grace VM. All trans retinoic_acid and cancer Immunopharmacol Immunotoxicol. 2011 Jun;33(2):241-9.
- 5: Ni X, Hu G, Cai X. The success and the challenge of all-trans retinoic_acid in the treatment of cancer Crit Rev Food Sci Nutr. 2019;59(sup1):S71-S80.
- 6: Belyaeva OV, Adams MK, Popov KM, Kedishvili NY. Generation of Retinaldehyde for Retinoic Acid Biosynthesis Biomolecules. 2019 Dec 18;10(1):5.
- 7: Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid J Lipid Res. 2002 Nov;43(11):1773-808.
- 8: Rosiles-Abonce A, Rubio C, Taddei E, Rosiles D, Rubio-Osornio M. Antiepileptogenic Effect of Retinoic_Acid Curr Neuropharmacol. 2021;19(3):383-391.
- 9: Samarawickrama C, Chew S, Watson S. Retinoic_acid and the ocular surface Surv Ophthalmol. 2015 May-Jun;60(3):183-95.
- 10: Thomas RM, Worswick S, Aleshin M. Retinoic acid for treatment of systemic sclerosis and morphea: A literature review Dermatol Ther. 2017 Mar;30(2).
